Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 27 recruiting now early-phase tilt #70 of 28,707 conditions

Influenza: early-phase trial registry

27 of 157 indexed Influenza trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #70 of 28,707 conditions by registered trial count.

157 US clinical trials · 27 currently recruiting · #70 of 28,707 conditions by registered trial count

Influenza: 157 US clinical trials tracked, 27 recruiting.

Influenza is the subject of 157 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 42 are in Phase 3-4 (later-stage) and 73 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 36 of these trials.

Enrollment posture brief

Registry condition influenza

OPEN 27 | RECR 17% | LATE 42 | EARLY 73 | RANK #70 | SPON 36

Nearest open-share peer: Arthritis, Rheumatoid (17% recruiting · 29 trials)

PTSD49.7%Gastric Cancer45.3%Obstructive Sleep Apnea42%Neoplasms31.3%Influenza (this)17%
Open-enrollment share among volume-matched conditions near Influenza

Influenza lists 27 open slots (17% of 157 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Influenza on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Influenza is recruiting below its size-band peers.

    27 of 157 indexed trials (17.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Influenza research.

    National Institute of Allergy and Infectious Diseases (NIAID) accounts for 36 of 157 trials (22.9%). 62 distinct sponsors appear on at least one study for this condition label.

  3. Typical Influenza enrolment sits around 219 participants.

    Median target enrolment is 219 among the 157 trials that report a genuine target (sentinel values excluded). 55 of those (35%) plan for fewer than 100 participants.

  4. Influenza research is mostly interventional.

    134 interventional and 23 observational studies make up this index (85.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 142Phase 231Phase 317Phase 425

Phase Distribution

PhaseTrial count
Phase 1 42
Phase 2 31
Phase 3 17
Phase 4 25

Named interventions

Most-linked intervention names on Influenza records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Biological
7 trials
Fluzone® Biological
5 trials
Oseltamivir Drug
5 trials
Baloxavir Marboxil Drug
5 trials
Placebo Drug
5 trials
Placebo Other
4 trials
Inactivated H1N1 Vaccine Biological
3 trials
GSK2340273A Biological
3 trials

US sites by state

Facility locations filed on Influenza trials. A trial with sites in several states counts in each.

California 45 trials
Maryland 34 trials
Texas 33 trials
Florida 32 trials
Georgia 30 trials
Ohio 29 trials
New York 27 trials
Missouri 26 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Influenza page

157 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Influenza condition card totals 157 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.